Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07463521) titled 'A Study to Evaluate the Efficacy and Safety of Rozanoloxizumab in Adult Participants With Ocular Myasthenia Gravis' on March 5.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).
Primary Sponsor: UCB Biopharma SRL
Condition:
Ocular Myasthenia Gravis
Intervention:
Drug: Rozanolixizumab
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: May 29, 2026
Target Sample Size: 120
To know more, visit https://clinicaltrials.gov/study/NCT07463521
...